RespireRx Pharmaceuticals Inc. Announces Entry into Option Agreement to License GABA(A) Receptor Allosteric Neuromodulator Intellectual Property from the UWM Research Foundation, Inc.
March 04, 2020 09:00 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., March 04, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the research and development of ampakines for a variety...
Global CNS Specific Antisense Oligonucleotide Market to Surpass US$ 6.8 Billion by 2026 – Coherent Market Insights
February 08, 2019 08:30 ET
|
CMI
SEATTLE, Feb. 08, 2019 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global CNS specific antisense oligonucleotide market is valued at US$ 883.7 million in 2017, and is projected to...
RespireRx Pharmaceuticals Inc. Announces Publication of Ampakine Data:
July 25, 2018 09:00 ET
|
RespireRX Pharmaceuticals Inc.
Effects of Chronic Systemic Low-impact Ampakine Treatment on Neurotrophin Expression in Rat Brain Glen Rock, N.J., July 25, 2018 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI)...
Advinus Therapeutics and P2D Bioscience Enter Into a Research and Development Collaboration for Attention Deficit Hyperactivity Disorder (ADHD)
July 24, 2012 08:35 ET
|
P2D Bioscience
CINCINNATI, OH and BANGALORE, INDIA--(Marketwire - Jul 24, 2012) - Advinus Therapeutics Ltd., a drug discovery and development company, and P2D Bioscience, a CNS-focused specialty...